Business
Vaxil: Management and Operational Update
Not for distribution by US newswire or in United States NESS-ZIONA, Israel, April 03, 2025 ...
About this update from Vaxil Bio Ltd.
[{"type":"text","content":"Vaxil: Management and Operational Update \n\n\n\n Not for distribution by US newswire or in United States\n \n\n\n NESS-ZIONA, Israel, April 03, 2025 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“\n \n Vaxil\n \n ” or the “\n \n Company\n \n ”) (TSX VENTURE: VXL), is pleased to make the following updates regarding the Company’s activities, management and operations.\n \n\n\n\n The Company is pleased to announce the Mr. Daniel Bloch, a current director of the Company has joined the audit committee of Vaxil, effective immediately. The audit committee now comprises Dr. Ari Kellen, Dr. Shawn Langer and Mr. Daniel Bloch, all independent directors.\n \n\n\n\n The board of directors remains unchanged, and comprises Mr. Gadi Levin (Chairperson and CEO), Dr. Ari Kellen (independent director), Dr. Shawn Langer (independent director) and Mr. Daniel Bloch (independent director).\n \n\n\n\n The Company further wishes to update its shareholders that the Company’s stock will resume trading on April 7, 2025 and that the TSXV has placed the Company on a 90-day notice to transfer to NEX board of the TSX Venture Exchange.\n \n\n\n\n Mr. Gadi Levin, the Company’s Chairperson and CEO said “The Company will continue to actively explore other strategic options for maximizing shareholder value.”\n \n\n\n\n Finaly, the Company advises that in order to preserve its cash resources, the Company will close its Israeli subsidiaries and absent cease to renew core patents.\n \n\n\n\n\n ABOUT VAXIL\n \n\n\n\n\n Vaxil is an Israeli immunotherapy biotech company focused on its novel approach to targeting prominent cancer markers and infectious diseases. Its lead product ImMucin™ completed a Phase 1/2 clinical trial in multiple myeloma for which it received orphan drug status from the FDA and EMA. The Company is presently evaluating whether to continue to develop ImMucin™ or to pursue other business, which may or may not be in the biotechnology industry, in order to enhance shareholder value.\n \n\n\n Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.\n \n\n\n Disclaimer: The TSX Venture Exchange Inc. has in no way passed upon the merits of the C...